Cofepris Opens Abbreviated Drug Registration Path via ANVISA

Media partner

PHARMA · SEPTEMBER 12, 2026 · LATIN AMERICA

An abbreviated registration pathway that treats Brazil’s regulatory verdicts as a credible starting point — rather than a parallel process to be replicated from scratch — is set to take effect in Mexico in mid-October 2026. The Comisión Federal para la Protección contra Riesgos Sanitarios (Cofepris), Mexico’s federal health-products regulator, has established the mechanism to accept evaluations conducted by the Agência Nacional de Vigilância Sanitária (ANVISA), Brazil’s national health surveillance agency, as the basis for an expedited review of drug registration applications, according to reporting by Consultor Salud.

The pathway covers a broad product scope: new molecular entities, generic medicines, innovative biotechnological products, biocomparable biotechnological products, biological products, and vaccines. Cofepris has set a maximum resolution timeframe of 45 business days — a ceiling that, if consistently met, would represent a material compression of the standard registration timeline for qualifying applicants. Cofepris retains final decision authority and preserves its verification, surveillance, and revocation powers, per the entity card derived from the agency’s own communications.

A reliance model with sovereignty intact

The mechanism is best understood as regulatory reliance rather than mutual recognition. The distinction matters commercially. Under mutual recognition, an approval in one jurisdiction automatically triggers approval in another. Under reliance, the reviewing authority uses a foreign regulator’s work product to inform — but not replace — its own decision. Cofepris’s explicit retention of verification and revocation powers places this squarely in the reliance category, which means manufacturers cannot treat an ANVISA clearance as a guaranteed Mexican approval. It is an accelerant, not a guarantee.

The move is consistent with a broader institutional trajectory. Since 2024, Cofepris has been advancing toward World Health Organization (WHO) Listed Authority (WLA) status — a designation that recognises regulators meeting the highest international standards — with technical support from the Pan American Health Organization (PAHO) and the European Union’s EU4Health programme, according to PAHO. A WHO technical team conducted an on-site benchmarking visit from 29 June to 3 July 2026 under the WHO’s Global Benchmarking Tool (GBT), per PAHO’s announcement. Víctor Borja, the Cofepris commissioner, described the process as part of ‘a long road we have already mapped out to improve,’ according to PAHO’s account of the session. Positioning ANVISA — itself one of the more stringent regulatory bodies in the Americas — as a reference authority is consistent with that upward alignment.

Mexico is described by PAHO as one of the first countries in the Americas to advance through the GBT mechanism in this manner, following El Salvador’s experience in 2018. That positioning suggests the abbreviated pathway is not an isolated procedural update but part of a deliberate effort to signal regulatory maturity to international manufacturers and multilateral bodies alike.

Commercial implications for dual-market manufacturers

For pharmaceutical companies that have already navigated ANVISA’s review — a process that encompasses bioequivalence, biodisponibility, and manufacturing-standards documentation — the new pathway reduces the marginal cost of entering Mexico. The 45-business-day ceiling, if operationally reliable, converts a Brazil approval into a regional asset rather than a country-specific one.

The product categories eligible for the pathway are broad enough to encompass most of the pipeline segments where manufacturers face the longest standard review queues: biologics, biosimilars, and new molecular entities. Generic medicines are also included, which may be of particular relevance given Cofepris’s longstanding generic-access agenda — the agency has authorised more than 540 generic medicines since 2012 across 21 disease areas representing approximately 70% of Mexico’s leading causes of death, according to PAHO’s 2018 reporting. The size of the applicant pool that holds current ANVISA approvals and lacks a Mexican registration has not been publicly disclosed.

The principal friction point is operational, not regulatory. A 45-business-day ceiling is a commitment, not a track record. Cofepris has historically faced administrative backlogs — its own documentation on registration prevention notices acknowledges that incomplete dossiers extend timelines and affect applicants’ commercial plans, per Cofepris’s published guidance. Whether the abbreviated pathway is staffed and resourced to meet its stated ceiling consistently is a question the available record does not yet answer. A pathway that resolves in 45 business days on paper but runs longer in practice offers manufacturers less certainty than the headline suggests.

A separate, pre-existing tension is also relevant. In June 2026, the Federación Mexicana de Colegios de Anestesiología (FMCA), Mexico’s federation of anaesthesiology colleges, issued an urgent communiqué warning that Cofepris’s introduction of fees and a more complex administrative process for controlled-substance prescription pads had increased bureaucratic load and could delay patient care, according to Infobae. The FMCA’s president, Gabriela Josefina Vidaña Martínez, held a virtual meeting with Cofepris staff to address the issue. The episode is a reminder that Cofepris is simultaneously managing multiple regulatory workstreams — some of which are generating friction with the clinical community — at the same time it is taking on an expanded reliance-review function.

No analyst estimate of the pathway’s commercial impact has been published in the available record. No named competitor or rival applicant has been identified in press materials as the first likely beneficiary of the mechanism.

The deeper implication is structural: by anchoring its abbreviated pathway to ANVISA rather than to the US Food and Drug Administration or the European Medicines Agency, Cofepris is signalling that intra-regional regulatory convergence — not just alignment with Northern Hemisphere standards — is a viable and deliberate policy direction. That choice shapes which manufacturers benefit first, and which regulatory investments carry the most regional leverage.